Danaher Corporation
DHR Healthcare Diagnostics & Research
Danaher Corporation’s revenue for fiscal 2025 (year ended December 2025) was $24.6 billion, up 2.90% from fiscal 2024. In the quarter to June 2026, revenue grew 5.54%, EPS grew 59.7%, free cash flow grew 15.6% and total debt rose 49.2%, each against the same quarter a year earlier. Member of the S&P 500.
Follow DHR
Danaher Corporation (DHR) P/S ratio
As of 16 October 2026, Danaher Corporation (DHR) trades at a P/S ratio of 6.4×. Over the past ten years it has ranged from 2.0× (April 2015) to 8.8× (August 2024); the current reading is higher than 67% of that period. That is above the Diagnostics & Research industry median of 4.4× and above the Healthcare sector median of 3.4×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 6.6× | (5.51%) |
| FY2024 | 7.0× | (2.90%) |
| FY2023 | 7.2× | 14.39% |
| FY2022 | 6.3× | (24.70%) |
| FY2021 | 8.4× | 34.66% |
| FY2020 | 6.2× | 14.90% |
| FY2019 | 5.4× | 44.58% |
| FY2018 | 3.8× | 2.25% |
| FY2017 | 3.7× | 28.50% |
| FY2016 | 2.9× | (5.30%) |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Jun 2026 | 5.4× | (1.22%) |
| Mar 2026 | 5.4× | (18.43%) |
| Dec 2025 | 6.6× | 14.38% |
| Sep 2025 | 5.8× | (1.49%) |
| 42 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| IQV IQVIA Holdings Inc. compare | 2.6× |
| TMO Thermo Fisher Scientific Inc. compare | 5.5× |
| DHR Danaher Corporation | 6.4× |
| A Agilent Technologies, Inc. compare | 6.6× |
| MTD Mettler-Toledo International, Inc. compare | 7.9× |
| ILMN Illumina, Inc. compare | 8.8× |
| WAT Waters Corporation compare | 9.2× |
| IDXX IDEXX Laboratories, Inc. compare | 9.7× |
| NTRA Natera, Inc. compare | 20.7× |
| Diagnostics & Research industry median | 4.4× |
| Healthcare sector median | 3.4× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on DHR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement